Modality
Radioligand
MOA
CDK4/6i
Target
JAK1
Pathway
mTOR
Schizophrenia
Development Pipeline
Preclinical
Jun 2020
→ Feb 2028
PreclinicalCurrent
NCT04427637
658 pts·Schizophrenia
2020-06→2028-02·Terminated
658 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-031.8y awayInterim· Schizophrenia
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Termina…
Catalysts
Interim
2028-02-03 · 1.8y away
Schizophrenia
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04427637 | Preclinical | Schizophrenia | Terminated | 658 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |